Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$2.21 USD
-0.08 (-3.49%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $2.20 -0.01 (-0.45%) 4:42 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 81 - 100 ( 270 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Promising Preclinical Data from Lead MicroRNA NASH Candidate at EASL
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q4/FY18 Financials; Near-Term Financing Risk Remains
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q1: Clarity on Potential Path Forward for RGLS4326/ADPKD Program Anticipated
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Preclinical GBM Data from Lead anti-miR-10b Compound Shows Survival Benefit
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q3 Financials; Near-Term Financing Risk; Key Catalyst for ADPKD in Q1:19
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Restructured Sanofi Collaboration Extends Cash Runway; Financing Risk Remains
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Pipeline Update and PT Adjustment for 1-for-12 Reverse Stock Split
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q2 Financials: Limited Upside While RG-012 Remains on Hold
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Downgrading to NEUTRAL: Significant Delays for RG-012 and RGLS4326
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q1 Financials: Kidney Pipeline Continues to Mature
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q4 Financials and 2018 Outlook: Selloff Overdone
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q4FY:17 Financials and Clinical Results for RG-012 and RGLS4329.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L